TransMedics Group (NASDAQ:TMDX) Given New $105.00 Price Target at JPMorgan Chase & Co.

TransMedics Group (NASDAQ:TMDX – Get Free Report) had its price objective upped by equities researchers at JPMorgan Chase & Co. from $87.00 to $105.00 in a research report issued on Tuesday, Benzinga reports. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of […]

Related Keywords

United States ,Stephen Gordon ,Riverpark Advisors ,First Horizon Advisors Inc ,Nasdaq ,Jpmorgan Chase Co ,Transmedics Group Stock Performance ,Morgan Stanley ,Analyst Recommendations For Transmedics Group ,Belpointe Asset Management ,Insider Activity At Transmedics Group ,Institutional Investors Weigh In On Transmedics Group ,Transmedics Group Inc ,News Ratings For Transmedics Group Daily ,Transmedics Group Company Profile ,Harbour Capital Advisors ,Transmedics Group ,Get Free Report ,Medics Group ,Capital Advisors ,Horizon Advisors ,Asset Management ,Investment Advisers ,Park Advisors ,Organ Care System ,Transmedics Group Daily ,Nasdaq Tmdx ,Tmdx ,Medical ,Boost Price Target ,Jpmorgan Chase Amp Co ,